Genetic screens in Caenorhabditis elegans models for neurodegenerative diseases

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1842, Issue 10, 2014, Pages 1951-1959

  Sin, Olga ^a,b   Michels, Helen ^a   Nollen, Ellen A A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

Caenorhabditis elegans; EMS; Genetic screen; Modifier gene; Nematode; Neurodegenerative disease; RNAi

Indexed keywords

ETHYL METHANE SULFATE; SULFATE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CAENORHABDITIS ELEGANS; CAG REPEAT; DEGENERATIVE DISEASE; GENE DISRUPTION; GENE MUTATION; GENE SILENCING; GENETIC SCREENING; HUMAN; HUNTINGTON CHOREA; MACHADO JOSEPH DISEASE; NONHUMAN; PARKINSON DISEASE; PROTEIN AGGREGATION; REVIEW; RNA INTERFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SPINOCEREBELLAR DEGENERATION;

EID: 84908498272     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2014.01.015     Document Type: Review

References (113)

1. Brenner S. The genetics of Caenorhabditis elegans. Genetics 1974, 77:71-94.
2. Fay D. Genetic mapping and manipulation: Chapter 1-Introduction and basics. The C. elegans Research Community February 17 2006, WormBook, (http://www.wormbook.org). 10.1895/wormbook.1.90.1. WormBook (Ed.).
3. Wolff S., Ma H., Burch D., Maciel G.A., Hunter T., Dillin A. SMK-1, an essential regulator of DAF-16-mediated longevity. Cell 2006, 124:1039-1053.
4. Gidalevitz T., Wang N., Deravaj T., Alexander-Floyd J., Morimoto R.I. Natural genetic variation determines susceptibility to aggregation or toxicity in a C. elegans model for polyglutamine disease. BMC Biol. 2013, 11:100.
5. C. elegans II. Section I, The Biological Model 1997, Cold Spring Harbor Laboratory Press, Cold Spring Harbor (NY). 2nd edition. D.L. Riddle, T. Blumenthal, B.J. Meyer (Eds.).
6. Gilbert S.F. Developmental Biology. Early Development of the Nematode Caenorhabditis elegans 2000, Sinauer Associates, Sunderland (MA). 6th edition.
7. The C. elegans sequencing consortium. Genome sequence of the nematode C. elegans: a platform for investigating biology. Science 1998, 282:2012-2018.
8. Dillin A., Hsu A.L., Arantes-Oliveira N., Lehrer-Graiwer J., Hsin H., Fraser A.G., Kamath R.S., Ahringer J., Kenyon C. Rates of behavior and aging specified by mitochondrial function during development. Science 2002, 298:2398-2401.
9. Lee S.S., Kennedy S., Tolonen A.C., Ruvkun G. DAF-16 target genes that control C. elegans life-span and metabolism. Science 2003, 300:644-647.
10. Kim Y., Sun H. Functional genomic approach to identify novel genes involved in the regulation of oxidative stress resistance and animal lifespan. Aging Cell 2007, 6:489-503.
11. Hamilton B., Dong Y., Shindo M., Liu W., Odell I., Ruvkun G., Lee S.S. A systematic RNAi screen for longevity genes in C. elegans. Genes Dev. 2005, 19:1544-1555.
12. Zipperlen P., Fraser A.G., Kamath R.S., Martinez-Campos M., Ahringer J. Roles for 147 embryonic lethal genes on C.elegans chromosome I identified by RNA interference and video microscopy. EMBO J. 2001, 20:3984-3992.
13. Keating C.D., Kriek N., Daniels M., Ashcroft N.R., Hopper N.A., Siney E.J., Holden-Dye L., Burke J.F. Whole-genome analysis of 60 G protein-coupled receptors in Caenorhabditis elegans by gene knockout with RNAi. Curr. Biol. 2003, 13:1715-1720.
14. Lai C.H., Chou C.Y., Chang L.Y., Liu C.S., Lin W. Identification of novel human genes evolutionarily conserved in Caenorhabditis elegans by comparative proteomics. Genome Res. 2000, 10:703-713.
15. Shaye D.D., Greenwald I. OrthoList: a compendium of C. elegans genes with human orthologs. PLoS ONE 2011, 6(5):e20085.
16. Jorgensen, Mango The art and design of genetic screens: Caenorhabditis elegans. Nat. Rev. Genet. 2002, 3(5):356-369.
17. Davis, et al. rapid single nucleotide polymorphism mapping in C. elegans. BMC Genomics 2005, 6:118.
18. Sarin, et al. Caenorhabditis elegans mutant allele identification by whole-genome sequencing. Nat. Methods 2008, 5(10):865.
19. Shen, et al. Comparing platforms for C. elegans mutant identification using high-throughput whole-genome sequencing. PLoS ONE 2008, 3(12):e4012.
20. Bigelow, et al. A software, MAQGene, facilitating C. elegans whole genome sequence analysis for mutant identification. Nat. Methods 2009, 6(8):549.
21. Tissenbaum, Guarente increased dosage of sir-2 gene extends lifespan in Caenorhabditis elegans. Nature 2001, 410(6825):227-230.
22. Burnett, et al. Absence of effects of Sir-2 overexpression on lifespan in C. elegans and Drosophila. Nature 2011, 477(7365):482-485.
23. Viswanathan, Guarente Regulation of Caenorhabditis elegans lifespan by sir-2.1 transgenes. Nature 2011, 477(7365):E1-E2.
24. Bargmann Neurobiology of the Caenorhabditis elegans genome. Science 1998, 282:2028-2033.
25. 2+ channel gene CACNL1A4. Cell 1996, 87:543-552.
26. Ferrari, et al. Serotonin metabolism in migraine. Neurology 1989, 39:1239-1242.
27. Kindt, et al. Serotonin promotes G(o)-dependent neuronal migration in Caenorhabditis elegans. Curr. Biol. 2002, 12(20):1738-1747.
28. Schafer, Kenyon A calcium-channel homologue required for adaptation to dopamine and serotonin in Caenorhabditis elegans. Nature 1995, 375(6526):73-78.
29. Estevez, et al. The voltage-gated calcium channel UNC-2 is involved in stress-mediated regulation of tryptophan hydroxylase. J. Neurochem. 2004, 88:102-113.
30. Bo, et al. Cerebrospinal fluid cytokine levels in migraine, tension-type headache and cervicogenic headache. Cephalalgia 2009, 29(3):365-372.
31. Sulston, Horvitz Abnormal cell lineages in mutants of the nematode Caenorhabditis elegans. Dev. Biol. 1981, 82(1):41-55.
32. Wang, Sternberg, et al. Pattern formation during C. elegans vulval induction. Curr. Top. Dev. Biol. 2001, 51:189-220.
33. Beitel, et al. The Caenorhabditis elegans gene lin-1 encodes an ETS-domain protein and defines a branch of the vulval induction pathway. Genes Dev. 1995, 9:3149-3162.
34. Jacobs, et al. Gain-of-function mutations in the Caenorhabditis elegans lin-1 ETS gene identify a C-terminal regulatory domain phosphorylated by ERK MAP Kinase. Genetics 1998, 149:1809-1822.
35. Egan, Weinberg The pathway to signal achievement. Nature 1993, 365(6449):781-783.
36. Pawson, Hunter Signal transduction and growth control in normal and cancer cells. Curr. Opin. Genet. Dev. 1994, 4(1):1-4.
37. Waterston, et al. The Genome. C. elegans II 1997, vol. 33:23-45. Cold Spring Harbor Laboratory Press, New York. Riddle, Blumenthal, Meyer, Priess (Eds.).
38. Fire, et al. Potent and specific genetic interference by double- stranded RNA in Caenorhabditis elegans. Nature 1998, 391(6669):806-811.
39. Timmons, et al. Inducible systemic RNA silencing in Caenorhabditis elegans. Mol. Biol. Cell 2003, 14(7):2972-2983.
40. Timmons, et al. Ingestion of bacterial expressed dsRNAs can produce specific and potent genetic interference in Caenorhabditis elegans. Gene 2001, 263(1-2):103-112.
41. Tabara, et al. RNAi in C. elegans: soaking in the genome sequence. Science 1998, 282(5388):430-431.
42. Tavernakis, et al. Heritable and inducible genetics interference by double-stranded RNA encoded by transgenes. Nat. Genet. 2000, 24(2):180-183.
43. Winston, et al. Systemic RNAi in C. elegans requires the putative transmembrane protein SID-1. Science 2002, 295(5564):2456-2459.
44. Hunter, et al. Systemic RNAi in Caenorhabditis elegans. Cold Spring Harb. Symp. Quant. Biol. 2006, 71:95-100.
45. Simmer, et al. Loss of putative RNA-directed RNA polymerase RRF-3 makes C. elegans hypersensitive to RNAi. Curr. Biol. 2002, 12(15):1317-1319.
46. Kennedy, et al. A conserved siRNA-degrading RNase negatively regulates RNA interference in C. elegans. Nature 2004, 427(6975):645-649.
47. Calixto, et al. Enhanced neuronal RNAi in C. elegans using SID-1. Nat. Methods 2010, 7(7):554-559.
48. Durieux, et al. The cell-non-autonomous nature of electron transport chain-mediated longevity. Cell 2011, 144(1):79-91.
49. Kamath, et al. Effectiveness of specific RNA-mediated interference through ingested double-stranded RNA in Caenorhabditis elegans. Genome Biol. 2001, 2(1). (research 0002.1-0002.10).
50. Kamath, et al. Systematic functional analysis of the Caenorhabditis elegans genome using RNAi. Nature 2003, 421(6920):231-237.
51. Wang, Barr RNA interference in Caenorhabditis elegans. Methods Enzymol. 2005, 392:36-55.
52. Rual, et al. Toward improving Caenorhabditis elegans phenome mapping with an ORFeome-based RNAi library. Genome Res. 2004, 14(10B):2162-2168.
53. Eliscovich, et al. mRNA on the move: the road to its biological destiny. J. Biol. Chem. 2013, 288(28):20361-20368.
54. Barrett, et al. Regulation of eukaryotic gene expression by the untranslated gene regioins and other non-coding elements. Cell. Mol. Life Sci. 2012, 69(21):3613-3634.
55. Maine Studying gene function in Caenorhabditis elegans using RNA-mediated interference. Brief. Funct. Genomic Proteomic 2008, 7(3):184-194.
56. Calixto, et al. Coditional gene expression and RNAi using MEC-8-dependent splicing in C.elegans. Nat. Methods 2010, 7(5):407-411.
57. Colaiácovo, et al. A targeted RNAi screen for genes involved in chromosome morphogenesis and nuclear organization in the Caenorhabditis elegans germline. Genetics 2002, 162(1):113-128.
58. Reinke, et al. A global profile of germline gene expression in C. elegans. Mol. Cell 2000, 6:605-616.
59. van Ham T.J., Thijssen K.L., Breitling R., Hofstra R.M., Plasterk R.H., Nollen E.A. C. elegans model identifies genetic modifiers of alpha-synuclein inclusion formation during aging. PLoS Genet. 2008, 4:e1000027.
60. van der Goot, et al. Delaying aging and the aging-associated decline in protein homeostasis by inhibition of tryptophan degradation. Proc. Natl. Acad. Sci. U. S. A. 2012, 109(37):14912-14917.
61. Simmer, et al. Genome-wide RNAi of C. elegans using the hypersensitive rrf-3 strain reveals novel gene functions. PLoS Biol. 2003, 1(1):E12.
62. van Ham T.J., Breitling R., Swertz M.A., Nollen E.A. Neurodegenerative diseases: lessons from genome-wide screens in small model organisms. EMBO Mol. Med. 2009, 1:360-370.
63. Soto C. Unfolding the role of protein misfolding in neurodegenerative diseases. Nat. Rev. Neurosci. 2003, 4:49-60.
64. Chiti F., Dobson C.M. Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 2006, 75:333-366.
65. Bolognesi B., Kumita J.R., Barros T.P., Esbjorner E.K., Luheshi L.M., Crowther D.C., Wilson M.R., Dobson C.M., Favrin G., Yerbury J.J. ANS binding reveals common features of cytotoxic amyloid species. ACS Chem. Biol. 2010, 20:735-740.
66. Arrasate M., Mitra S., Schweitzer E.S., Segal M.R., Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 2004, 14:805-810.
67. Bessou C., Giugia J.B., Franks C.J., Holden-Dye L., Ségalat L. Mutations in the Caenorhabditis elegans dystrophin-like gene dys-1 lead to hyperactivity and suggest a link with cholinergic transmission. Neurogenetics 1998, 2:61-72.
68. Morley J.F., Brignull H.R., Weyers J.J., Morimoto R.I. The threshold for polyglutamine expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:10417-10422.
69. Hamamichi S., Rivas R.N., Knight A.L., Cao S., Caldwell K.A., Caldwell G.A. Hypothesis-based RNAi screening identifies neuroprotective genes in a Parkinson's disease model. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:728-733.
70. Kuwahara T., Koyama A., Koyama S., Yoshina S., Ren C.H., Kato T., Mitani S., Iwatsubo T. A systematic RNAi screen reveals involvement of endocytic pathway in neuronal dysfunction in alpha-synuclein transgenic C. elegans. Hum. Mol. Genet. 2008, 17:2997-3009.
71. Link C.D. Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:9368-9372.
72. Wittenburg N., Eimer S., Lakowski B., Roèhrig S., Rudolph C., Baumeister R. Presenilin is required for proper morphology and function of neurons in C. elegans. Nature 2000, 406:306-309.
73. Cohen E., Bieschke J., Perciavalle R.M., Kelly J.W., Dillin A. Opposing activities protect against age-onset proteotoxicity. Science 2006, 313:1604-1610.
74. Cohen E., Paulsson J.F., Blinder P., Burstyn-Cohen T., Du D., Estepa G., Adame A., Pham H.M., Holzenberger M., Kelly J.W., Masliah E., Dillin A. Reduced IGF-1 signaling delays age-associated proteotoxicity in mice. Cell 2009, 139:1157-1169.
75. Kraemer B.C., Burgess J.K., Chen J.H., Thomas J.H., Schellenberg G.D. Molecular pathways that influence human tau-induced pathology in Caenorhabditis elegans. Hum. Mol. Genet. 2006, 15:1483-1496.
76. van Ham T.J., Holmberg M.A., van der Goot A.T., Teuling E., Garcia-Arencibia M., Kim H.E., Du D., Thijssen K.L., Wiersma M., Burggraaff R., van Bergeijk P., van Rheenen J., van Veluw G.J., Hofstra R.M., Rubinsztein D.C., Nollen E.A. Identification of MOAG-4/SERF as a regulator of age-related proteotoxicity. Cell 2010, 20:601-612.
77. Lejeune F.X., Mesrob L., Parmentier F., Bicep C., Vazquez-Manrique R.P., Alex Parker J., Vert J.P., Tourette C., Neri C. Large-scale functional RNAi screen in C. elegans identifies genes that regulate the dysfunction of mutant polyglutamine neurons. BMC Genomics 2012, 13:91.
78. Komatsu M., Wang Q.J., Holstein G.R., Friedrich V.L., Iwata J., Kominami E., Chait B.T., Tanaka K., Yue Z. Essential role for autophagy protein Atg7 in the maintenance of axonal homeostasis and the prevention of axonal degeneration. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:14489-14494.
79. Blum E.S., Schwendeman A.R., Shaham S. PolyQ disease: misfiring of a developmental cell death program?. Trends Cell Biol. 2013, 23:168-174.
80. Faber P.W., Alter J.R., MacDonald M.E., Hart A.C. Polyglutamine-mediated dysfunction and apoptotic death of a Caenorhabditis elegans sensory neuron. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:179-184.
81. Parker J.A., Connolly J.B., Wellington C., Hayden M., Dausset J., Neri C. Expanded polyglutamines in Caenorhabditis elegans cause axonal abnormalities and severe dysfunction of PLM mechanosensory neurons without cell death. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:13318-13323.
82. Brignull H.R., Moore F.E., Tang S.J., Morimoto R.I. Polyglutamine proteins at the pathogenic threshold display neuron-specific aggregation in a pan-neuronal Caenorhabditis elegans model. J. Neurosci. 2006, 26:7597-7606.
83. Nollen E.A., Garcia S.M., van Haaften H.G., Kim S., Chavez A., Morimoto R.I., Plasterk R.H. Genome-wide RNA interference screen identifies previously undescribed regulators of polyglutamine aggregation. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:6403-6408.
84. Silva M.C., Fox S., Beam M., Thakkar H., Amaral M.D., Morimoto R.I. A genetic screening strategy identifies novel regulators of the proteostasis network. PLoS Genet. 2011, 7:e1002438.
85. Falsone S.F., Meyer N.H., Schrank E., Leitinger G., Pham C.L., Fodero-Tavoletti M.T., Holmberg M., Dulle M., Scicluna B., Gesslbauer B., Rückert H.M., Wagner G.E., Merle D.A., Nollen E.A., Kungl A.J., Hill A.F., Cappai R., Zangger K. Cell. Reprogram. 2012, 2:358-371.
86. de Lau L.M., Breteler M.M. Epidemiology of Parkinson's disease. Lancet Neurol. 2006, 5:525-535.
87. Inamdar N.N., Arulmozhi D.K., Tandon A., Bodhankar S.L. Parkinson's disease: genetics and beyond. Curr. Neuropharmacol. 2007, 5:99-113.
88. Przedborski S., Dauer W. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
89. Chung K.K., Zhang Y., Lim K.L., Tanaka Y., Huang H., Gao J., Ross C.A., Dawson V.L., Dawson T.M. Parkin ubiquitinates the α-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat. Med. 2001, 7:1144-1150.
90. Abeliovich A., Schmitz Y., Fariñas I., Choi-Lundberg D., Ho W.H., Castillo P.E., Shinsky N., Verdugo J.M., Armanini M., Ryan A., Hynes M., Phillips H., Sulzer D., Rosenthal A. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 2000, 25:239-252.
91. Lavedan C. The synuclein family. Genome Res. 1998, 8:871-880.
92. Clayton D.F., George J.M. The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci. 1998, 21:249-254.
93. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045-2047.
94. Krüger R., Kuhn W., Müller T., Woitalla D., Graeber M., Kösel S., Przuntek H., Epplen J.T., Schöls L., Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 1998, 18:106-108.
95. Zarranz J.J., Alegre J., Gómez-Esteban J.C., Lezcano E., Ros R., Ampuero I., Vidal L., Hoenicka J., Rodriguez O., Atarés B., Llorens V., Gomez Tortosa E., del Ser T., Muñoz D.G., de Yebenes J.G. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 2004, 55:164-173.
96. Chartier-Harlin M.C., Kachergus J., Roumier C., Mouroux V., Douay X., Lincoln S., Levecque C., Larvor L., Andrieux J., Hulihan M., Waucquier N., Defebvre L., Amouyel P., Farrer M., Destée A. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004, 364:1167-1169.
97. Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., Hulihan M., Peuralinna T., Dutra A., Nussbaum R., Lincoln S., Crawley A., Hanson M., Maraganore D., Adler C., Cookson M.R., Muenter M., Baptista M., Miller D., Blancato J., Hardy J., Gwinn-Hardy K. Alpha-synuclein locus triplication causes Parkinson's disease. Science 2003, 302:841.
98. Fung, et al. Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol. 2006, 5:911-916.
99. Collins B.M., McCoy A.J., Kent H.M., Evans P.R., Owen D.J. Molecular architecture and functional model of the endocytic AP2 complex. Cell 2002, 109:523-535.
100. Bettens K., Sleegers K., Van Broeckhoven C. Genetic insights in Alzheimer's disease. Lancet Neurol. 2013, 12:92-104.
101. Ballard C., Gauthier S., Corbett A., Brayne C., Aarsland D., Jones E. Alzheimer's disease. Lancet 2011, 377:1019-1031.
102. Myers A.J., Kaleem M., Marlowe L., Pittman A.M., Lees A.J., Fung H.C., Duckworth J., Leung D., Gibson A., Morris C.M., de Silva R., Hardy J. The H1c haplotype at the MAPT locus is associated with Alzheimer's disease. Hum. Mol. Genet. 2005, 14:2399-23404.
103. Caffrey T.M., Wade-Martins R. Functional MAPT haplotypes: bridging the gap between genotype and neuropathology. Neurobiol. Dis. 2007, 27:1-10.
104. McGoll G., Roberts B.R., Gunn A.P., Perez K.A., Tew D.J., Masters C.L., Barnham K.J., Cherny R.A., Bush A.I. The Caenorhabditis elegans Aß1-42 model of Alzheimer disease predominantly expresses Aß3-42. J. Biol. Chem. 2009, 284:22697-22702.
105. Link C.D., Taft A., Kapulkin V., Duke K., Kim S., Fei Q., Wood D.E., Sahagan B.G. Gene expression analysis in a transgenic Caenorhabditis elegans Alzheimer's disease model. Neurobiol. Aging 2003, 24:397-413.
106. Wu Y., Wu Z., Butko P., Christen Y., Lambert M.P., Klein W.L., Link C.D., Luo Y. Amyloid-beta-induced pathological behaviors are suppressed by Ginkgo biloba extract EGb 761 and ginkgolides in transgenic Caenorhabditis elegans. J. Neurosci. 2006, 26:13102-13113.
107. McColl G., Roberts B.R., Pukala T.L., Kenche V.B., Roberts C.M., Link C.D., Ryan T.M., Masters C.L., Barnham K.J., Bush A.I., Cherny R.A. Utility of an improved model of amyloid-beta (Aβ1-42) toxicity in Caenorhabditis elegans for drug screening for Alzheimer's disease. Mol. Neurodegener. 2012, 7:57.
108. Miyasaka T., Ding Z., Gengyo-Ando K., Oue M., Yamaguchi H., Mitani S., Ihara Y. Progressive neurodegeneration in C. elegans model of tauopathy. Neurobiol. Dis. 2005, 20:372-383.
109. Brandt R., Gergou A., Wacker I., Fath T., Hutter H. A Caenorhabditis elegans model of tau hyperphosphorylation: induction of developmental defects by transgenic overexpression of Alzheimer's disease-like modified tau. Neurobiol. Aging 2009, 30:22-33.
110. Wang H.Y., Li W.W., Benedetti N.J., Lee D.H.S. Alpha(7) nicotinic acetylcholine receptors mediate beta-amyloid peptide-induced tau protein phosphorylation. J. Biol. Chem. 2003, 278:31547-31553.
111. Kaletta T., Hengartner M.O. Finding function in novel targets: C. elegans as a model organism. Nat. Rev. Drug Discov. 2006, 5:387-398.
112. Treusch S., Hamamichi S., Goodman J.L., Matlack K.E., Chung C.Y., Baru V., Shulman J.M., Parrado A., Bevis B.J., Valastyan J.S., Han H., Lindhagen-Persson M., Reiman E.M., Evans D.A., Bennett D.A., Olofsson A., DeJager P.L., Tanzi R.E., Caldwell K.A., Caldwell G.A., Lindquist S. Functional links between Aβ toxicity, endocytic trafficking, and Alzheimer's disease risk factors in yeast. Science 2011, 334:1241-1245.
113. Shulman J.M., Chipendo P., Chibnik L.B., Aubin C., Tran D., Keenan B.T., Kramer P.L., Schneider J.A., Bennett D.A., Feany M.B., De Jager P.L. Functional screening of Alzheimer pathology genome-wide association signals in Drosophila. Am. J. Hum. Genet. 2011, 88:232-238.